SCHEMBL7793341

SCHEMBL7793341

O=C(c1cc(-c2ccccc2)co1)c1cc(-c2ccccc2)co1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA4 P43681 1/20 0.51
CTRC Q99895 1/20 0.45
PTGER4 P35408 1/20 0.45
ABCC4 O15439 1/20 0.41
LMNA P02545 1/20 0.41
GAA P10253 1/20 0.41
TSHR P16473 1/20 0.41
PTGS1 P23219 1/20 0.41
HTT P42858 1/20 0.41
ALDH1A1 P00352 2/20 0.40
HPGD P15428 1/20 0.40
MMP1 P03956 1/20 0.40
MMP2 P08253 1/20 0.40
MMP3 P08254 1/20 0.40
KMO O15229 1/20 0.39
FFAR1 O14842 1/20 0.38
FLT3 P36888 1/20 0.38
GSTA1 P08263 1/20 0.38
MAPT P10636 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3737353 0.88 PTGER4 (0.57) CHRNA4CTRCPTGER4ABCC4LMNA
SCHEMBL7285067 0.84 CHRNA4 (0.49) CHRNA4CTRCPTGER4ABCC4LMNA
SCHEMBL27679068 0.81 CHRNA4 (0.50) CHRNA4CTRCPTGER4ABCC4LMNA
SCHEMBL27605092 0.80 LMNA (0.42) CHRNA4LMNAMAPT
SCHEMBL27811533 0.80 CHRNA4 (0.49) CHRNA4PTGER4LMNAGAATSHR
SCHEMBL13044154 0.80 CHRNA4 (0.46) CHRNA4CTRCPTGER4LMNAGAA
SCHEMBL16691872 0.78 RAB9A (0.56) CHRNA4LMNATSHRALDH1A1HPGD
SCHEMBL11795907 0.78 PTGER4 (0.49) CHRNA4PTGER4LMNATSHRALDH1A1
SCHEMBL27624018 0.78 CYP2A6 (0.50) ALDH1A1KMO
SCHEMBL28878980 0.78 CNR2 (0.55) GAATSHRALDH1A1HPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010056085-A1 Methods of using vesicant drug formulations RAMU AVNER (US) 2001-12-27 US claimed
US-20010056085-A1 Methods of using vesicant drug formulations RAMU AVNER (US) 2001-12-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010056085-A1 Methods of using vesicant drug formulations UGT1A1, SLC47A1, UGT1A10 CHRNA4 3718/4885CTRC 1292/4885PTGER4 898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.